Soon after, it became part of clinical practice and has been recommended for the first-line treatment of advanced NSCLC tumors with no driver gene mutation, such as epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement, and those with a PD-L1 expression tumor proportion score (TPS) of ≥1% [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.